Januarys Rotary Youth of the… – Renton Reporter

Rotary members recognize three Renton School District high school students each month as Youth of the Month.

After being selected by counselors at each of the districts three comprehensive high schools, a selection committee of Rotary members review applications and interview students to identify those who will be selected as Youth of the Month.

The award is given to students who possess leadership abilities, maintain a good grade point average, participate in school activities and volunteer in their community.

January Rotary Youth of the Month are:

Megan Fung

Senior at Hazen High School

Megan holds a 3.9 GPA; she has been involved in Band, Key Club, HOSA, STEM Club and National Honor Society. She has received Solo and Ensemble Band ratings of Excellent and Superior and Outstanding Marcher Award.

Megan volunteers with the Bellevue Arts Museum, KidsQuest, local schools, Seattle Reign and many other fundraising events in the community.

She plans to attend a four-year university to major in a STEM field, like engineering and would like to intern at labs during her college years to gain experience and prepare for a career after she completes her degree. At this time, she hopes to become a chemical engineer.

Lauren Huynh

Senior at Hazen High School

Lauren holds a 3.9 GPA; she has been involved in Hazen Drill Team, Key Club, Philharmonic Orchestra, National Honor Society, Gordy Guides and Earth Corps. She has received Hazen Academic All-Star (multiple times), Soundview Orchestra Superior Ratings, Drill Team Academic State Champions, Varsity Letters, District and State Drill Awards, and 2019 National Drill Champion.

Outside of school, Lauren has been taking piano and viola lessons for many years.

She plans to attend a four-year college or university to study architecture or design and is interested in working as an interior designer for staging homes, hotels or businesses.

Connor Donahue

Senior at Lindbergh High School

Connor holds a 3.9 GPA; he has been involved in Key Club, National Honor Society, Class Senator, College Access Now, Eagle Crew and Lindbergh Swim. He has received AP Scholar with Distinction, Perfect Score-SAT II World History, Department Student of the Month, Outstanding Junior Award, OSHA and Microsoft JAVA Certification, Eagle of the Year Award, and State and District Swim placements/awards.

Connor works part-time as a lifeguard for the City of Renton and volunteers with Birthday Dreams and the Chinook Aquatic Club.

Hes planning to attend a private four-year college to pursue a degree in engineering or economics and is interested in a career in a STEM related field such as biochemistry or nuclear engineering.

Samirah Apdalhaliem

Senior at Renton High School

Samirah holds a 3.9 GPA; she has been involved in HOSA Club, Renton Peer Mentor, Renton Multicultural Festival and Renton High Tennis. She has received Honor Roll, Department Award and Citizenship/Academic Award.

Samirah works at the Samena Swim and Recreation Club as a front desk member and has spent time volunteering with the Woodland Park Zoo, Cham Refugee Community, Fred Hutchinson Cancer Research Center and the Bill and Melinda Gates Foundation.

She is planning to attend a four-year university, in Washington, majoring in Biology-Physiology. She hopes to continue her education to attend the University of Washington Medical School and pursue a career in medicine to give back to her community.

Read more:
Januarys Rotary Youth of the... - Renton Reporter

Genetics to be discussed Jan. 19 – Cleveland Jewish News

Genetics: Testing, Editing and Ethics for the Future will be discussed from 9:30 to 10:45 a.m. Jan. 19 at Unitarian Universalist Congregation of Cleveland, 2100 Shaker Blvd. in Shaker Heights

Aaron Goldenberg, Case Western Reserve University associate professor in the department of bioethics and co-director, Center for Genetic Research, Ethos and Law and Marsha Michie, assistant professor in the department of bioethics at the CWRU School of Medicine, will lead the discussion.

See the original post here:
Genetics to be discussed Jan. 19 - Cleveland Jewish News

Scientist Who Discovered BRCA1 Gene to Give Free Talk on Cancer And Genetics – Noozhawk

By Caitlin O'Hara for UCSB Arts & Lectures | January 15, 2020 | 9:00 a.m.

UCSB Arts & Lectures and the Cancer Foundation of Santa Barbara co-present Understanding Genetics and Cancer, a free community event featuring Mary-Claire King, the scientist who discovered the BRCA1 gene,7:30 p.m. Thurs., Feb. 6, at UCSB Campbell Hall.

King's lecture will be followed by a panel of experts discussing genetics, cancer and you, providing resources and answering pertinent questions

UCSB Arts & Lectures and the Santa Barbara Cancer Foundation will present a free community event Understanding Genetics and Cancer, featuring a lecture by human geneticist Mary-Claire King, the scientist who discovered the BRCA1 gene.

Her talk, at 7:30 p.m. Thursday, Feb. 6, at UCSB Campbell Hall, will be followed by a panel of experts discussing genetics, cancer and you.

King discovered the genetic mutation responsible for breast cancer, a finding that has revolutionized the course of cancer research and transformed the way patients are diagnosed and treated.

A recipient of the National Medal of Science for her bold, imaginative and diverse contributions to medical science and human rights, Dr. King will discuss the genetics of inherited cancers.

Following the talk, a panel of experts will address genetics, cancer and you, including the following topics:

Lifestyle and cancer risk reductionFamily history and ethnicity risk factorsGenetic testing as cancer preventionPrivacy of genetic testing resultsBenefits and perils of ancestry testingLocal resources for cancer risk assessment and counseling

King is American Cancer Society professor in the Department of Medicine and the Department of Genome Sciences at the University of Washington in Seattle. She was the first to show that breast cancer is inherited in some families, as the result of mutations in the gene that she named BRCA1.

In addition to inherited breast and ovarian cancer, her research interests include the genetic bases of schizophrenia, the genetic causes of congenital disorders in children, and human genetic diversity and evolution.

King pioneered the use of DNA sequencing for human rights investigations, developing the approach of sequencing mitochondrial DNA preserved in human remains, then applying this method to the identification of kidnapped children in Argentina and subsequently to cases of human rights violations on six continents.

King grew up in Chicago. She received her bachelor's degree cum laude in mathematics from Carleton College in Northfield, Minn.; her doctorate in genetics from the University of California at Berkeley; and her postdoctoral training at UC San Francisco.

Her Ph.D. dissertation with Allan Wilson was the demonstration that protein-coding sequences of humans and chimpanzees are 99 percent identical. She was professor at UC Berkeley from 1976-95 and at the University of Washington in Seattle since 1995.

King has served on multiple councils and study sections of the N.I.H. and the U.S. National Academy of Sciences. She was consultant to the Commission on the Disappearance of Persons of the Republic of Argentina and carried out DNA identifications for the United Nations War Crimes Tribunals.

She is past president of the American Society of Human Genetics and a past member of the Council of the National Academy of Sciences. King has been elected to the American Academy of Arts and Sciences, the National Academy of Medicine, American Philosophical Society, and as a foreign member of the French Academy of Sciences.

Understanding Genetics and Cancer is co-presented by UCSB Arts & Lectures and the Cancer Foundation of Santa Barbara in association with Breast Cancer Resource Center, Ridley-Tree Cancer Center at Sansum Clinic, Santa Barbara Neighborhood Clinics and UCSB Department of Molecular, Cellular and Developmental Biology.

Sponsored by the Cancer Foundation of Santa Barbara, supporter of the Ridley-Tree Cancer Center and its Genetic Counseling Program.

For more, call UCSB Arts & Lectures, 805-893-3535 or visit http://www.ArtsAndLectures.UCSB.edu.

UCSB Arts & Lectures acknowledges Community Partners the Natalie Orfalea Foundation & Lou Buglioli and Corporate Season Sponsor SAGE Publishing for their support of the 2019-20 season.

Caitlin O'Hara for UCSB Arts & Lectures.

Read the original post:
Scientist Who Discovered BRCA1 Gene to Give Free Talk on Cancer And Genetics - Noozhawk

Veritas Genetics Restarts US Business With Near-Term Financing – GenomeWeb

NEW YORK Veritas Genetics has restructured its business and is reopening its US operations with a small team of core employees, GenomeWeb has learned.

According to CEO Mirza Cifric, the company has secured an undisclosed amount of near-term financing from unnamed investors, allowing it to restart the US business. In addition, he said the firm is working on closing "a significant round of funding." He declined to elaborate on the potential investors.

Visit link:
Veritas Genetics Restarts US Business With Near-Term Financing - GenomeWeb

BTYSTE 2020: From eco-friendly dollhouses to the genetics of clever dogs VIDEO – Siliconrepublic.com

We visited theBT Young Scientist and Technology Exhibition again this year, getting the chance to chat to some of the countrys brightest students.

There were project posters stretching to all corners of the main hall at the RDS, filled with excited participants waiting for their visit from the judging panel.

Hugh Murtagh from Coliste Mhuire in Westmeath took us through hisA-Ok project a discreet wristband that students with autism can wear to let their teacher know if theyre feeling overwhelmed at school.

I have autism and I know just how hard it is to try and focus in class when you feel overwhelmed. I want to try and help people like me and people who also have autism, he said.

We also learned about an eco-powered dollhouse with the potential to teach children about climate action, how mental health can be impacted by climate change, and whether genetics affects how clever a dog breed is.

>> READ MORE

Words by Lisa Ardill

See the article here:
BTYSTE 2020: From eco-friendly dollhouses to the genetics of clever dogs VIDEO - Siliconrepublic.com

JPM: How will Amgen make its $13.4B Otezla buy pay off? New launches, for one, CEO says – FiercePharma

SAN FRANCISCOWhen Amgen shelled out $13.4 billion late last year to pick up Celgene's blockbuster immunology med Otezla, it made a calculated guess the drug had some untapped fuel in its commercial tank. Now, Amgen is looking to rev up sales with new indications and launches in new international markets.

Although scant on details, Amgen CEO Bob Bradway forecast Tuesdaythat Amgen could squeeze more out of Otezla in the coming yearsafter the drug hit $547 million in sales in the third quarterassuming Amgen can follow its own mantra and execute.

"In biopharma, the focus is on innovation, innovation, innovation, and Amgen is execution, execution, execution," Bradway told investors at the annual J.P. Morgan Healthcare Conference in San Francisco.

Artificial Intelligence in the Pharma Industry

How far has the adoption of AI technology come in Life Sciences? Share your thoughts in this brief, 8-minute survey. Let your voice be heard.

In Bradway's telling, Otezla helped Amgen flesh out its immunology portfolio as a counterpart to stalwart Enbrel.

"We think the stars really aligned for us in 2019 when we were able to acquire Otezla," Bradway said. "Otezla is a great medicine, it has great valuefor us, and it came at a great time."

RELATED:Amgen, maker of Enbrel, to pick up Celgene's Otezla for $13.4B. Will FTC hit back?

Amgen picked up Otezla in a$13.4 billion deal with Celgene in August as the latter worked to secure its$74 billion merger with Bristol-Myers Squibb.

Bristol was forced to sell Otezla to win the Federal Trade Commission's clearance simply because it overlappedwith BMS own investigational TYK-2 inhibitor, BMS-986165. Despite Amgen's blockbuster Enbrel operating in the same market, the deal passed muster.

At the time, Amgen expected Otezla could enjoy at least low double-digit sales growth on average over the next five years. The Streets consensus currently has it reaching $2.5 billion in peak sales before presumably going off patent in the U.S. in 2028. At that rate,Amgen will at least be able to get its investment back in full by around 2024.

Looking ahead, Amgen expects phase 3 data for Otezla in mild to moderate psoriasis will read out this year, and the drugmaker hopes to launch the drug beyond the30-oddinternational markets where it's currently approved, Bradway said.

Excerpt from:
JPM: How will Amgen make its $13.4B Otezla buy pay off? New launches, for one, CEO says - FiercePharma

Why There’s No Such Thing as a Truly Hypoallergenic Dog – Healthline

If you become congested and start to sneeze anytime youre near a dog, youre not alone. The American College of Allergy, Asthma, and Immunology (ACAAI) reports that almost 10 million people are allergic to their pets.

For many pet owners, buying a hypoallergenic dog sounds like the perfect solution. No more allergy pills or shots and you can still have a cute, furry friend. It sounds perfect, right?

However, when Healthline asked several allergy experts about hypoallergenic dogs, they all gave us a very emphatic no.

Theres no such thing as a truly hypoallergenic dog.

However, there are many options to consider that may allow you to own a dog without triggering a reaction if youre a person living with pet allergies.

According to allergist Dr. Tania Elliott, a spokesperson for the ACAAI, people can develop allergic reactions to pet dander (similar to dandruff in humans), saliva, urine, and hair.

When exposed to these substances, our body can mistakenly see certain proteins within them, called allergens, as a threat. To protect us, our body develops antibodies against those proteins.

When were exposed to those proteins again, we then have an allergic response. Our immune system will be activated, causing the release of histamine.

Histamine causes symptoms, such as sneezing and increased mucus production, which protect us from the invading protein.

These symptoms are what cause the discomfort we associate with an allergy.

In the case of a dog allergy, Elliott says you could develop symptoms such as itchy eyes, runny nose, asthma attacks, sneezing, and/or congestion.

You might also develop hives if youve been touched or licked by a dog.

According to Dr. Jill A. Poole, professor, division chief of allergy and immunology at the department of medicine at the University of Nebraska Medical Center, theres no such thing as a hypoallergenic dog because all dogs produce the same proteins.

Its those proteins to which youre reacting. Thats why even a so-called hypoallergenic dog can still trigger an allergic reaction.

It would be more appropriate, Poole said, to call these shedding versus non-shedding dogs.

Shedding dogs release more dog hair into their environment, leading to a buildup of dog hair in your home.

Non-shedding dogs tend to not shed their hair as easily. They must be regularly groomed to prevent matting.

When dogs shed, some people can develop an irritant response to the hair.

While the symptoms can be the same, an irritant response is different from an allergic response. Irritation doesnt trigger the production of antibodies the way an allergy does.

If you experience an irritant response to dog hair, having a dog that sheds less would reduce this.

Being vigilant about keeping loose dog hair cleaned up would also help those who are experiencing an irritant response, says Poole.

Poole says your first step in getting tested for a dog allergy would be to talk with a doctor or allergist about your symptoms and medical history. If these indicate a possible dog allergy, they can order a test for you.

This testing would be either a skin test or a blood test.

Skin and blood tests are similar in that they can detect the antibodies in your skin and blood that trigger an immune response to a particular allergen.

In a skin test, a small amount of a diluted allergen is placed under your skin, either by pricking the skin or by injection.

If you develop a red, itchy bump, called a wheal, within about 15 minutes, youre considered to be allergic to that particular allergen.

A blood test would involve drawing blood and testing it in a laboratory for the presence of antibodies.

While theres no such thing as a hypoallergenic dog, it appears that some people with dog allergies may not be allergic to all dogs.

Theres recent research indicating that people who are allergic to a specific dog protein called Can f 5 might only react to intact male dogs.

Poole explains this means that some people with dog allergies could potentially own either a female or a neutered male dog and wouldnt have an allergic reaction.

There are six different proteins that have been been identified as causing allergies in dogs: Can f 1 to 6.

Can f 5 is only produced in the prostate gland of the male.

Because of this fact, a female dog wouldnt produce an allergic reaction in people who are allergic to only this one allergen.

A neutered male produces less of this protein and might also be a safe choice.

About 30 percent of people with dog allergies are allergic to only the Can f 5 protein, Poole says.

Dr. Princess Ogbogu, director of allergy and immunology at Ohio State University Wexner Medical Center, does caution that its a bit premature to make this a standard clinical recommendation.

It is a hypothesis and not well established yet, Ogbogu said.

However, if youd like to explore this avenue further, you can speak with your doctor about testing.

A test for allergy to the Can f proteins was approved by the Food and Drug Administration in May 2019.

Poole says its important that youre tested for all of the Can f allergens and not just Can f 5. You could be allergic to more than one of them.

If youre not one of the lucky few who are only allergic to Can f 5, there are several other steps you can take that may allow you to have a canine in your home.

Poole suggests the first place to start is to try limiting your exposure to the offending allergens through environmental controls.

According to the ACAAI, environmental controls could include such things as:

Another step you can take is to use medications to manage your allergy symptoms.

Your allergist can recommend which medications will be best for you, depending on your individual symptoms.

Medications your doctor might prescribe include:

Finally, although it can be time-consuming, immunotherapy does offer more of a permanent solution to dog allergies.

Poole explains it takes about 3 to 5 years to desensitize a person to an allergen.

The protocol involves giving the person a gradually increasing dose of the allergen once or twice a week until they reach a maintenance dose.

At this point, theyd then need an injection every 2 to 4 weeks over the course of about 3 to 5 years.

Each injection is given subcutaneously (in the fat layer between the skin and muscle).

The person is then observed by a medical professional for 30 minutes in case they have an adverse reaction to the allergen.

Immunotherapy can greatly reduce, or even completely eliminate, your allergy symptoms.

Many people who love dogs are unfortunately allergic to them.

While a hypoallergenic dog might seem like a good solution, allergy experts say theres really no such thing as a hypoallergenic dog.

However, this doesnt mean youre without options. There are ways to reduce or eliminate your exposure to dog allergens. You can also take medications that manage your symptoms or have immunotherapy to desensitize you to dog allergens.

An allergist can help you learn more about your options.

Read more here:
Why There's No Such Thing as a Truly Hypoallergenic Dog - Healthline

Attack of the Clones? Memory CD8+ T Cells Stalk the AD, PD Brain – Alzforum

14 Jan 2020

As if the neurodegenerative brain didnt have enough troubles, a study published in Nature on January 8 reports that it may be swarming with highly trained cellular henchmen. Researchers led by Tony Wyss-Coray at Stanford University found cytotoxic CD8+ T cells in the cerebrospinal fluid and brain tissue of people with Alzheimers and Parkinsons disease. Far from merely surveying the brain, they had multipliedclonally expanded, in immunology parlancesuggesting they were fighting specific antigens. To what were they responding? For most of the clones, this remains a mystery. However, a small proportion of T cells in three AD patients recognized a snippet of Epstein-Barr virus, a herpesvirus known to infect cells of the CNS.

This beautiful study shows, for the first time, a close association between T cells, cognition, and neurodegenerative disease in humans, wrote Jonathan Kipnis of University of Virginia in Charlottesville. These elegant findings on expansion of Epstein-Barr virus-reactive CD8 T cells in the CSF of AD patients are extremely interesting and intriguing, he added.

Neuroinflammation has moved to center stage in neurodegenerative disease research, but most work focuses on the innate, rather than adaptive, immune system. Still, evidence implicating the adaptive immune system has been quietly trickling in over the years. For example, scientists detected T cells specific for A and -synuclein in the blood of AD and PD patients, respectively (Bongioanni et al., 1997; Monsonego et al., 2003; Jun 2017 news).While dogma holds that T cells are scarce in the brain, a recently discovered lymphatic drainage system there carries T cells, making it clear that adaptive immune cells can, and do, frequent the CNS (Louveau et al., 2015; Oct 2017 news; Oct 2019 news). Some studies detected more T cells in the brains of people with neurodegenerative disease than in healthy brains (Togo et al., 2002; Town et al., 2005; Sept 2009 news).

In the new study, first author David Gate and colleagues set out to clarify what the adaptive immune system might do in Alzheimers. First, they took stock of immune cell populations in the blood, reporting that people with MCI or AD had more of a subtype of CD8+ T cells than did cognitively unimpaired controls. Specifically, high numbers of a subset of T effector memory cells expressing CD45RA, turned up in AD and MCI. Also known as T-EMRA cells, they are renowned for their killing efficiency, Gate told Alzforum. They rapidly dispense with any cells they recognize and also secrete a slew of proinflammatory cytokines.

In a separate cohort, the researchers found that the more circulating T-EMRA cells a person with AD or MCI had, the worse he or she performed on cognitive tests. Numbers of circulating T-EMRA cells predicted MCI or AD with 80 percent accuracy, suggesting that this particular subset of T cells in the blood was somehow tied to the neurodegenerative process in the brain.

Infiltrating the AD Brain. CD8+ T cells (green) congregate in blood vessels laden with cerebral amyloid angiopathy, and around Aplaques (red). [Courtesy of Gate et al., Nature, 2020.]

Could these cells also be in the brain, then? Immunohistochemistry on postmortem brain samples identified more CD8+ T cells in hippocampal parenchyma and adjacent leptomeninges of seven AD patients than of seven controls. The cells congregated around A plaques and neuronal processes. Gate also found numerous CD8+ T cells associated with the blood vessels affected by cerebral amyloid angiopathy in three AD patients, but found nary a T cell around the vasculature of controls. Gate did not measure other markers to determine whether these were T-EMRA cells.

Caught in the Act? A CD8+ T cell (red) in the hippocampus of an AD brain contains cytotoxic granules loaded with Granzyme A, a protein that kills target cells. [Courtesy of Gate et al., Nature, 2020.]

Gate spotted adaptive immune cells in the CSF as well. Most were T cells, but he was surprised to find 20 percent were CD8+, and of those, again 20 percent were T-EMRA. Were they just passing through, or carrying out an immunological hit? To find out, the researchers sequenced T cell receptor genes of individual T cells, which are unique due to the recombination that generates the TCRs. The existence of even two cells with identical receptor sequence indicates clonal expansion, and this occurs only when the killers encounter their cognate antigen (aka prey).

The scientists report evidence of numerous expanded clones in the CSF of 12 people with either MCI or AD (see image below). Clonal expansion was far less common among 10 controls. While one out of 10 healthy controls had a highly expanded clonei.e., one that comprised at least 3 percent of all TCR sequencesfour of six AD patients and one of five people with MCI did.

Moreover, individual clones detected in AD CSF had expanded to a greater degree than those from controls. One AD patient had a CD8+ T cell clone that comprised a whopping 44 percent of all CD8+ T cells in their CSF. Roughly two-thirds of all expanded CD8+ T cell clones belonged to the T-EMRA subset; the other third were T effector memory (T-EM) cells.

Clonal Expansion. Doughnuts show the T-cell pool in the CSF. While a majority of T cells from healthy controls were unique, i.e. not expanded (white), a majority of T cells in AD CSF had clonally expanded two to four times (orange), five to nine times (blue), or more than 10 times (green). For expanded clones, each colored wedge represents the percentage of total TCRs in the pool. Being too numerous, unique clones (white) are not represented by wedges. [Courtesy of Gate et al., Nature, 2020.]

The researchers also found more clonal expansions in the CSF of six people with PD, including two people with highly expanded clones, than in 10 controls. This suggested the phenomenon is not limited to AD.

The cells did not appear benign. Using single-cell RNA sequencing, the researchers found that the most highly expanded T-cell clones in the CSF expressed a bevy of pro-inflammatory cytokine and cytotoxic proteins, including Granzyme A, also made by CD8+ T cells in AD patients. The findings imply that these CNS T cells were killing cells that waved their specific antigenic flags in the brain, commented Terrence Town of the University of Southern California in Los Angeles. Granzyme A is the smoking gun, Town added.

To which antigens were these clones responding? For most of the clones, this question is unanswered. Employing TCR sequencing with a large helping of computational wizardry, the researchers identified T-cell clones in two people with AD and one with MCI that carried the T-cell receptors recognizing the same antigenan epitope from the EBNA3 protein in Epstein-Barr virus. EBV is a herpes virus known to infect the brain. Using an unbiased machine-learning approach, the researchers also picked up T cells in two other patients that reacted to yet another epitope from EBVthis one came from the EBV trans-activator protein BZLF1. No common expanded TCRs were found among controls.

The presence of the EBV-specific T cells is intriguing, but in no way establishes a link between EBV and AD, wrote Howard Weiner and Dennis Selkoe of Brigham & Womens Hospital in Boston in a joint comment to Alzforum. Weiner and Selkoe previously identified T cells specific for A and -synuclein in the blood of AD and PD patients.

The findings dont implicate EBV in the pathogenesis of AD. However, Gate speculated that stress and inflammation in the diseased brain could trigger reactivation of latent EBV, which could lead to recruitment of EBV-specific T cells and the slaughter of any infected neurons. Alternatively, or perhaps additionally, changes at the blood-brain barrier could let more T cells into the brain, Gate added. Town wondered whether damage to the integrity of the blood-brain barrier in vessels wracked with cerebral amyloid angiopathy could explain how CD8+ T cells gained access to those regions.

Guillaume Dorothe of INSERM in Paris said that the T-cell clones in the CSF could reflect clonal expansion that took place outside the brain. Perhaps the cells were responding to peripheral antigens, and then were unselectively recruited to the CSF of inflamed brain, he said. A direct comparison of T-cell clones in the blood and CSF of the same patients could help clarify this point, he added. Defining whether parenchymal T cells share antigen specificities with the clones patrolling the CSF will also be important, Dorothe noted. Regardless of what drove the cells into the CSF and brain, their presence supports the idea that T cells play some part in the neurodegenerative process, and that targeting them could alter the course of disease, he said. Dorothes previous studies in AD mice suggest that amplifying regulatory T cells, which control immune responses including T-cell immunity, slowed disease progression (Dansokho et al., 2016).

Gate did not test how many of the patients had been infected with EBV, nor directly measure EBV infection in brain samples. In a commentary accompanying the paper, Michael Heneka of the German Center for Neurodegenerative Diseases in Bonn urged caution in interpreting the findings. He noted that more than 95 percent of people are infected by EBV in their lifetime, but a previous study detected EBV DNA in only 6 percent of AD brains (Carbone et al., 2014).

Several studies have tied Alzheimers to various viruses, particularly herpes, though their connection to AD pathophysiology remains controversial (Itzhaki et al., 1997; Jun 2018 news;Jun 2018 news).Jessica Shugart

Here is the original post:
Attack of the Clones? Memory CD8+ T Cells Stalk the AD, PD Brain - Alzforum

Gilead Backs Startup Kyverna Therapeutics with Financing, Collaborative Agreement – BioSpace

Gilead Sciencesis boosting support for a Bay Area startup looking to develop a new class of therapies for autoimmune diseases. Gilead, along with two venture capital groups, provided Kyverna Therapeutics with an infusion of $25 million and also struck a collaboration with the fledgling company.

On Monday, Kyverna announced it had closed a $25 million Series A investment from Gilead, Vida Ventures and Westlake Village BioPartners, which will be used to advance the companys platform that combines advanced T cell engineering and synthetic biology technologies to suppress and eliminate autoreactive immune cells at the root cause of inflammatory disease. In addition to the cash, Gilead and Kyverna entered into a collaboration and license agreement to develop engineered T cell therapies for the treatment of autoimmune disease based on Kyverna's synthetic Treg platform and synNotch technology from Gilead subsidiary Kite Pharma. Kyverna will be responsible for conducting research activities and initial clinical studies through proof-of-concept. Gilead will be granted an option to continue to develop and potentially commercialize any product that comes from the research.

Under terms of this agreement, Gilead will pay Kyverna $17.5 million in upfront cash. Kyverna could earn an additional $570 million in development and commercialization milestones, depending on how the research goes.

Dominic Borie, chief executive officer of Kyverna, called it one of the most exciting times in the industry when a new modality has the potential to become the backbone of treatment for a variety of severe immune-related diseases. Borie is an immunologist and transplant surgeon who joins Kyverna from Horizon Therapeutics where he served as head of External Research and Development. Prior to Horizon, Borie served in numerous leadership functions within Genentech focused on global clinical development of immunology therapies including two anti-CD20 molecules (rituximab and obinutuzumab) in development for orphan immunology indications. Before that, Borie was with Amgen where he served as Medical Director and Global Development Leader for Inflammation.

In addition to Borie, the Kyverna team includes Jeffrey Greve, who will serve as the companys chief scientific officer. Prior to Kyverna, Greve founded and served as CSO of Delinia, an autoimmune disease company acquired by Celgene in 2017.

As part of the $25 million Series A, Fred Cohen, co-founder and senior managing director of Vida Ventures will serve as chairman of Kyvernas board of directors.

We are just beginning to see the potential for cell therapy and the opportunity to change the course of disease... At Vida, we have a long-standing commitment to advancing cell therapy. We believe the team at Kyverna, under Dominic's stewardship and in partnership with Dr. Greve, the architect of the Kyverna scientific platform, has the ability to develop a new class of therapies for serious autoimmune diseases, Cohen said in a statement.

Go here to read the rest:
Gilead Backs Startup Kyverna Therapeutics with Financing, Collaborative Agreement - BioSpace

Kyverna Therapeutics Secures $25 Million Series A Funding from Key Investors and Enters into Strategic Collaboration with Gilead Sciences – PRNewswire

As part of this financing, Fred Cohen, M.D., D.Phil., Co-Founder and Senior Managing Director of Vida Ventures will serve as Chairman of the Board. Beth Seidenberg, M.D., Co-Founding Managing Director of Westlake Village BioPartners, Desmond Padhi, B.Sc., Pharm. D., Principal at Westlake Village BioPartners,Brian Kotzin, M.D., Senior Vice President of Nektar Therapeutics, Peter Emtage, Ph.D., Senior Vice President, Global Head of Research, Kite, a Gilead Company, one additional representative from Vida Ventures to be named, and Dominic Borie, M.D., Ph.D., will serve on the Company's the Board of Directors.

"We are just beginning to see the potential for cell therapy and the opportunity to change the course of disease. Dominic's skill as an immunologist and transplant surgeon, coupled with his proven leadership skill as an executive in the biopharmaceutical industry is what we require to embark on our bold vision for Kyverna," said Fred Cohen, M.D., D.Phil., Co-Founder and Senior Managing Director of Vida Ventures. "At Vida, we have a long-standing commitment to advancing cell therapy. We believe the team at Kyverna, under Dominic's stewardship and in partnership with Dr. Greve, the architect of the Kyverna scientific platform, has the ability to develop a new class of therapies for serious autoimmune diseases."

"This may be one of the most exciting times is our industry where a new modality has the potential to become the backbone of treatment for a variety of severe immune-related diseases," said Dominic Borie, M.D., Ph.D., newly appointed CEO of Kyverna. "This opportunity perfectly unites my experience as a surgeon, academic and drug developer with my passion for finding cures for autoimmune diseases. I am proud to serve as Kyverna's CEO and be a part of this team."

Kyverna also announced that it has entered into a strategic collaboration and license agreement with Gilead to develop engineered T cell therapies for the treatment of autoimmune disease based on Kyverna's synthetic Treg platform and synNotch technology from Kite, a Gilead Company. Kyverna will be responsible for conducting research activities and initial clinical studies through proof-of-concept and Gilead will be granted an option, upon the exercise of which Gilead will be solely responsible for further clinical development and commercialization efforts for these programs. Gilead will make to Kyverna an upfront payment of $17.5 million and Kyverna may earn an additional $570 million in development and commercialization milestones. Kyverna will also continue to advance its platform and develop proprietary programs beyond the Gilead collaboration.

"Kyverna's approach combines advanced T cell engineering and synthetic biology technologies to develop significant new therapies for autoimmune and inflammatory diseases," said Beth Seidenberg, M.D., Co-Founding Managing Director of Los Angeles-based Westlake Village BioPartners. "The strategic collaboration with Gilead Sciences in autoimmune diseases enables Kyverna to apply its therapeutic approach to this important unmet need."

Dr. Borie is an accomplished immunologist and digestive tract and liver transplant surgeon with extensive experience in drug development. He joins Kyverna from Horizon Therapeutics where he served as Vice-President and Head, External Research and Development. Prior to Horizon, Dr. Borie served in numerous leadership functions within Genentech focused on global clinical development of immunology therapies including two anti-CD20 molecules (rituximab and obinutuzumab) in development for orphan immunology indications. Dr. Borie had joined Genentech from Amgen where he served as Medical Director and Global Development Leader for Inflammation. He started his career in industry at Roche as Director of Transplantation research before transitioning to Translational Medicine roles for inflammation. Prior to the transition to industry, Dr. Borie was in academia at Stanford University as the Director, Transplantation Immunology Laboratory where he became a key contributor in the validation of JAK inhibition as a new immunomodulatory approach to treating rheumatoid arthritis. Dr. Borie was previously a digestive surgery and liver transplantation attending surgeon at Pitie- Salpetriere Hospital, Assistance Publique in Paris, France. He received his Ph.D. in transplantation immunology from the University of Paris V - Descartes and his M.D., Master's degree in Immunology and Certificate of Immunology and Immunopathology from the University of Paris XII.

About Vida VenturesVida Ventures is a next-generation life sciences investment firm founded by a group of scientists, physicians, entrepreneurs and investors passionate about building and funding breakthroughs in biomedicine. Together they form an independent, bold investment group bound together by a simple word life. Its mission is to bring science to life and advance transformative biomedical innovations that have the potential to make a meaningful difference for patients. Vida has a bicoastal presence and currently has approximately $1 billion under management. For more information on Vida Ventures, please visit http://www.vidaventures.com, on LinkedIn or follow on Twitter @Vida_Ventures.

About Westlake Village BioPartnersWestlake Village BioPartners is a Los Angeles area-based venture capital firm focused on incubating and building life sciences companies with entrepreneurs that have the potential to bring transformative therapies and technologies to patients. The Westlake model is built on the founding team's unique experience in successfully identifying and developing breakthrough therapies and building organizations. For more information, please visithttp://westlakebio.com/.

About Kyverna TherapeuticsKyverna Therapeutics, located in the San Francisco East Bay, is a cell therapy company engineering a new class of therapies for serious autoimmune diseases. The Kyverna therapeutic platform combines advanced T cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the root cause of inflammatory diseases. For more information, please visit http://kyvernatx.com/.

synNotch is a registered trademark of Kite Pharma, Inc.

SOURCE Kyverna Therapeutics

Homepage

More here:
Kyverna Therapeutics Secures $25 Million Series A Funding from Key Investors and Enters into Strategic Collaboration with Gilead Sciences - PRNewswire